The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | The relevance of SCT in multiple myeloma
Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, discusses the role of stem cell transplantation (SCT) in multiple myeloma, highlighting data from key clinical trials. The benefit of upfront SCT has been shown on multiple occasions and notably in the IFM 2009 trial (NCT01191060), which demonstrated that upfront transplant led to deeper measurable residual disease (MRD) negativity and longer progression-free survival (PFS). In addition, the FORTE trial comparing carfilzomib plus lenalidomide plus dexamethasone (KRd) followed by autologous stem cell transplantation (ASCT) and maintenance therapy versus KRd alone followed by maintenance therapy showed a superior PFS for both standard and high-risk patients undergoing early transplant. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
